Our research

Most rare brain diseases have no known cause in most patients. Pooling genomes from many families is how new risk genes are found.

The problem

Diseases like progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy are rare, hard to diagnose during life, and usually not clearly inherited. Each research group sees only a handful of patients, too few to find genetic signals.

Our approach

  • Whole genomes, not just tests for single genes. We collect complete genome and exome data so new genes, not only known ones, can be found.
  • Confirmed diagnoses. We link genomes to brain bank and autopsy findings wherever families allow, because clinical diagnosis is often wrong for these diseases.
  • Families, not just individuals. DNA from affected and unaffected relatives helps tell which variants matter.
  • Data that families control. Each family sets the rules for how its data is used, and we enforce them before anything is shared.

Questions we want to answer

  • Which genes, beyond MAPT, raise the risk of PSP and CBD?
  • Why do some carriers of a known disease gene become ill decades earlier than others?
  • Which unsolved families carry a new, undiscovered cause?
  • Can genetic profiles help match patients to the right clinical trials?

Publications

Our first results will be listed here as they are published.